by Lance Smith | Dec 3, 2019 | Study Scavenger Clinical Trial Recruitment Platform
Phase 2a clinical trial for topical cerdulatinib to enroll 30 patients with vitiligo Top-line results anticipated in second half of 2020 BASEL, Switzerland and LONG BEACH, Calif., Dec. 03, 2019 (GLOBE NEWSWIRE) — Dermavant Sciences, a dermatology-focused...by Lance Smith | Dec 3, 2019 | Study Scavenger Clinical Trial Recruitment Platform
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today it has completed patient enrollment in its...by Lance Smith | Dec 3, 2019 | Study Scavenger Clinical Trial Recruitment Platform
Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced the completion of enrollment in its ongoing double-blind, randomized, placebo-controlled...by Lance Smith | Dec 3, 2019 | Study Scavenger Clinical Trial Recruitment Platform
TrialScope, in conjunction with EMD Serono, has launched a new clinical trials website. The site is designed to inform the public and healthcare professionals about clinical trials in general and provide details on EMD Serono clinical trials. EMD Serono Clinical...by Lance Smith | Dec 3, 2019 | Study Scavenger Clinical Trial Recruitment Platform
BOTHELL, Wash., and TOKYO, Dec. 2, 2019 /PRNewswire/ — Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), today announced a clinical collaboration agreement with Merck,...by Lance Smith | Dec 3, 2019 | Study Scavenger Clinical Trial Recruitment Platform
SALT LAKE CITY, Dec. 3, 2019 /PRNewswire/ — Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced the dosing of the first participant enrolled in the REPAIR-PD study with its lead nanocatalytic therapy, CNM-Au8, for the treatment...